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Background: Autotransporter proteins represent a treasure trove for molecular engineers who modify
Gram-negative bacteria for the export or secretion of foreign proteins across two membrane barriers. A particularly
promising direction is the development of autotransporters as antigen display or secretion systems. Immunologists
have been using ovalbumin as a reporter antigen for years and have developed sophisticated tools to detect
specific T cells that respond to ovalbumin. Although ovalbumin-expressing bacteria are being used to trace T cell
responses to colonizing or invading pathogens, current constructs for ovalbumin presentation have not been
optimized.
Results: The activation of T helper cells in response to ovalbumin was improved by displaying the OVA-CD4
reporter epitope as a multimer on the surface of Salmonella and fused to the autotransporter MisL. Expression
was optimized by including tandem in vivo promoters and two post-segregational killing systems for plasmid
stabilization.
Conclusions: The use of an autotransporter protein to present relevant epitope repeats on the surface of bacteria,
combined with additional techniques favoring stable and efficient in vivo transcription, optimizes antigen
presentation to T cells. The technique of multimeric epitope surface display should also benefit the development
of new Salmonella or other enterobacterial vaccines.
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Escherichia coli is the prototype bacterium used for the
production of desired foreign proteins in vitro. A par-
ticularly interesting approach has been the export of for-
eign proteins on the bacterial surface of E. coli by taking
advantage of the specific inherent properties of autotran-
sporter proteins. These proteins, which represent a cat-
egory of type V secretion systems of Gram-negative
bacteria, are exported to the periplasm by the sec ma-
chinery and assembled into the outer membrane by the
Bam and Tam proteins [1-3]. The carboxy-terminal end
of an autotransporter protein forms a beta-barrel struc-
ture with a central pore originally thought to channel
the amino-terminal side of the protein or passenger* Correspondence: dmschiff@vet.upenn.edu
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unless otherwise stated.domain to the bacterial surface. Newer models propose
that Bam participates in making the pore, implying that
the term “autotransporter” is a misnomer [3]. For some
autotransporter proteins, the translocated segment is
cleaved and released from the bacteria, which can be
useful for direct purification procedures from spent
medium. Some cleaved translocators remain surface as-
sociated by non-covalent bond. Whether secreted or on
the bacterial surface, translocators can act as adhesins,
mediators of biofilm formation, enzymes for intercellular
spreading, cytotoxins or modulators of immune re-
sponses [3]. Early studies recognized the use of autotran-
sporters as export machineries for foreign proteins and
antigens. Translocator domains of a variety of autotran-
sporter proteins have been modified with in-frame fu-
sions of recombinant proteins for display on the
bacterial surface or for delivery to the spent medium
[4,5]. Among these autotransporters, the SalmonellaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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engineered to express four copies of the Plasmodium fal-
ciparum immunodominant epitope (NANP) on the sur-
face of Salmonella enterica [7]. MisL was able to express
even more copies of NANP on E. coli and to release
them in the medium after the addition of a cleavage site
for the surface protease OmpT [8]. The epitopes were
shown to induce immune responses. Similarly, viral and
parasitic protein epitopes were successfully expressed by
recombinant MisL on Salmonella vaccine strains and in-
duced epitope-specific immune responses with protect-
ive properties [9,10].
Here, we took advantage of the transport property of
MisL to export a fused antigenic model peptide on the
surface of Salmonella as an activation signal for specific
cellular immune responses. The generation of a T helper
cell 1 (Th1) immune response is crucial for successful
control of the facultative intracellular pathogen Salmon-
ella and several studies have highlighted the importance
of the CD4+ T cell response during infection [11]. The
ability to track antigen specific T cells is important for
understanding the initiation and maintenance of T cell
responses during various infections and in response to
vaccines [12]. Since endogenous T cells specific for any
given antigen are present in small numbers, it makes the
tracking of such cells difficult during the early phases of
an immune response before clonal expansion has oc-
curred. Adoptive transfer models using TCR-transgenic
T cells specific for model antigens such as ovalbumin
have thus provided a vital tool for tracking antigen spe-
cific T cell responses [13-15]. A key aspect of such stud-
ies is to obtain efficient and stable expression of a
foreign antigen by a genetically engineered pathogen.
The expression systems in Salmonella using full-length
ovalbumin constructs available thus far have resulted in
suboptimal responses in vivo [16-18]. The current inves-
tigation highlights the use of a novel construct based on
the polymeric surface display of an ovalbumin reporter
epitope to amplify the signal for the improved activation
and detection of cognate CD4+ T cells.
Results
Construction, expression and export of the MisL-OVA-CD4
fusion proteins
The Salmonella autotransporter protein MisL was used
to display a specific MHC class II ovalbumin peptide
(OVA-CD4) on the surface of a Salmonella vaccine vec-
tor. The OVA-CD4 peptide was fused through genetic
engineering to the N-terminus of the translocator do-
main of MisL. The construct was based on the pnirLTB-
MisL plasmid [7] that encodes a truncated MisL protein
with the signal sequence of the heat-labile enterotoxin of
E. coli in frame. This truncated MisL lacks the amino-
terminal 423 amino acids of the mature MisL. Theexpressed MisL protein included an additional 210
amino acids of its alpha domain to avoid potential pro-
tein misfolding in the periplasm and ensure correct con-
formation in the outer membrane for transit of the
passenger domain to the bacterial surface and display of
its N-terminus [7,8]. The plasmid used the nirB pro-
moter that is activated under the anaerobic conditions of
the intestinal environment and induces improved sys-
temic immune responses towards foreign antigen
expressed by orally administered Salmonella vaccine
strains [19-21]. This vector is not a high copy number
plasmid as antibody responses against antigens delivered
by Salmonella are improved when expressed from low
to medium copy number plasmids that minimize meta-
bolic stress upon the carrier strain [22,23]. Previous
addition of the spiC promoter, which is activated in
antigen-presenting cells, was used successfully to express
the MisL protein or the 987P fimbriae of E. coli as viral
epitope carriers on the surface of a Salmonella vaccine
vector. Oral immunization experiments in mice also sug-
gested improved in vivo expression by showing better
humoral immune responses against the foreign antigens
[10,24]. Thus, we prepared a similar promoter tandem
construct by inserting the spiC promoter between the
nirB promoter and the Shine Delgarno site for MisL
transcription (Figure 1). Expression of the OVA-CD4-
MisL fusion protein was evaluated with Salmonella
strain SL7207 carrying either pZS1202 (nirBp) or
pZS1204 (nirBp and spiCp). Using an antibody specific
for the OVA-CD4 epitope, the fusion protein of ex-
pected size (approximately 60 kDa) was detected by
western blot analysis for both constructs with approxi-
mately three times more protein being expressed when
both promoters were used, as determined by densitom-
etry (Figure 2A). The OVA-CD4 specific antibody was
confirmed to react with ovalbumin but not with Salmon-
ella-expressing MisL alone. The detection of the fusion
protein in Salmonella grown under aerobic conditions
suggests some promoter leakiness, although the high af-
finity of the anti-OVA-CD4 antibody used in these as-
says might render detection very sensitive. Previous data
indicated that magnesium activated fimbrial subunit
gene expression from the spiC promoter in a phoP mu-
tant [24]. However, using the same mutant strain, a sig-
nificant effect due to magnesium was not detectable for
MisL, possibly due to the fact that MisL is a much larger
protein than the previously studied fimbrial subunit. In
order to demonstrate that the OVA-CD4-MisL fusion
protein was crossing the cytoplasmic membrane and be-
haved like the native MisL protein, outer membranes
prepared from strain SL7207 carrying the plasmid with
the misL fusion gene were analyzed by western blotting.
The OVA-CD4-MisL fusion protein was detected in the
outer membrane preparation using the ovalbumin-
Figure 1 Plasmid constructions, as described in Methods.
Figure 2 Expression of OVA-CD4pep-MisL fusion proteins
determined by western blot analysis using an anti-OVA-CD4
peptide polyclonal antibody (A) Ovalbumin (lane 1), strain
CS4551 with pnirBLTBsp-MisL (lanes 2 and 3), pZS1202 which
expresses the (OVA-CD4)-MisL fusion protein from the nirB
promoter (lanes 4 and 5), or pZS1204 expresses the (OVA-CD4)-
MisL fusion protein from the nirB and spiC promoters in tandem
(lanes 6 and 7); (B) Bovine serum albumin (lane 1), ovalbumin
(lane 2), untreated (lane 3) or proteinase K-treated (lane 4) outer
membrane proteins of Salmonella strain SL7207 pZ1204.
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fusion protein was not affected in its export and
localization properties. Moreover, fused OVA-CD4 pep-
tide was susceptible to proteinase K degradation, charac-
terizing its accessibility on either one or both outer
membrane surfaces.
Stabilized plasmids
To ensure that attenuated Salmonella strains would
keep the OVA-CD4-MisL plasmid construct in the ab-
sence of antibiotic selection after administration to
mammalian hosts, two post-segregational killing systems
from the F plasmid of E. coli, the fimAB and ccdAB
genes were engineered into the plasmid (Figure 1). Effi-
ciency of plasmid maintenance was investigated by
growing Salmonella SL7207 with or without the stabi-
lized plasmid in antibiotic-free media for approximately
530 generations. The plasmid-bearing rate was calcu-
lated by dividing the number of bacteria recovered from
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antibiotic-free plates. As shown in Figure 3, plasmid
pZS1204 with no stabilization system was gradually lost
during after 20 daily passages, however plasmid pZS1205
was kept in essentially all the bacteria. A derivative of the
latter plasmid, pZS1205-4, which expresses four copies of
the OVA-CD4 was 100% maintained for one week and in
nearly half of the bacteria for 26 days. In contrast, the high
copy number plasmid pUC18-OVA that constitutively
expressed the full-length ovalbumin protein was lost in
five days. These results confirmed that high copy number
plasmid constructs have the undesirable effect of being
unstable in the absence of antibiotic selection. More im-
portantly, the data demonstrated that the fimAB and
ccdAB genes have an efficient plasmid stabilization prop-
erty that prolongs the life span of foreign antigen-
expressing Salmonella.
Surface exposure of the OVA-CD4 epitope peptide on
Salmonella
To determine whether the OVA-CD4 portion of the fusion
protein was located on the periplasmic or extracellular face
of the outer membrane, intact Salmonella expressing the
fusion protein were subjected to treatments with various
concentrations of proteinase K. Presence of the OVA-CD4
peptide was then determined by western blot analysis with
the OVA-CD4 specific antibodies (Figure 4A). ParallelFigure 3 Plasmid segregational stability. Salmonella SL7207 with
the stabilized pZS1205 plasmid (☐) or the nonstabilized pZS1204
plasmid (￭), each expressing (OVA-CD4)-MisL, with the stabilized
pZS1205-4 (△) that expresses four copies of OVA-CD4 fused to MisL,
or pUC18-OVA (▲) that expresses full-length ovalbumin were grown
in LB broth at 37°C without antibiotics. Serial passages were conducted
daily by diluting the overnight cultures into fresh media (10−3 dilutions
for the first week and 10−5 dilutions for later). Plasmid stability was
estimated by calculating the numbers of ampicillin-resistant CFUs
divided by the total number of CFUs and multiplying the number by
100 to obtain a percentage of bacteria containing the plasmid.western blots were probed for the periplasmic β-lactamase
with an anti-ampicillinase antibody to evaluate concentra-
tions of proteinase K that would be effective on the bac-
terial surface without permeating into the periplasmic
compartment (Figure 4B). Proteinase K at a concentration
of 11 μg/ml completely degraded the OVA-CD4 peptide
without affecting the periplasmic β-lactamase, indicating
that the latter peptide was exposed on the bacterial sur-
face. A comparable result was obtained with higher con-
centrations of proteinase K, albeit a partial proteolytic
effect on the β-lactamase suggested some permeation of
the protease.
Construction and display of oligomeric OVA-CD4 epitopes
on the surface of Salmonella
Having engineered OVA-CD4 encoded DNA to be
flanked by restriction sites with matching 5′ extensions
(XbaI and NheI) on plasmid pZS1205, it was possible to
construct new homocomposite plasmids that add OVA-
CD4 peptides in tandem to the amino-terminal end of
MisL. We prepared plasmids capable of expressing MisL
fusion proteins carrying dimeric and tetrameric OVA-
CD4 epitopes and compared their levels of expression
and surface display. Western blot analysis of these con-
structs showed that each addition of OVA-CD4 epitope
copies to MisL significantly increased expression of the
fusion protein (Figure 4C). Densitometry of the steady-
state detectable proteins indicated that the (OVA-CD4)
2-MisL dimer and (OVA-CD4)4-MisL tetramer con-
structs had approximately 2.7 and 4.8 times more OVA-
CD4 epitopes, respectively, than the (OVA-CD4)1-MisL
monomeric epitope fusion protein. We speculated that
the lower molecular bands seen with the OVA tetramer
were due to degradation of surface epitopes by the outer
membrane protease PgtE [24], therefore we repeated the
experiment with an insertion mutant of Salmonella
SL7207 deficient for PgtE expression. Densitometry re-
vealed greatly reduced degradation products for the
tetramer construct and 1.7 and 4.4 times more OVA-
CD4 epitopes were expressed with the dimer and tetra-
mer MisL fusion proteins compared to the monomer
construct (Figure 4D). All the ovalbumin epitopes
expressed by Salmonella were accessible to the protein-
ase K proteolytic activity, consistent with their surface-
exposure. The increased numbers of smaller products
for the tetramer construct in the absence of proteinase
K pointed towards bacterial auto-degradation processes.
Surface display of the OVA-CD4 epitope was visually
confirmed by fluorescence microscopy. Using the OVA-
CD4 specific antibody with a FITC-labeled secondary
antibody to label the surface of Salmonella SL7207 ex-
pressing one, two or four copies of OVA-CD4 fused to
MisL, the intensity of the fluorescence increased accord-
ingly, as determined by the number of additional epitope
Figure 4 Surface exposure of (OVA-CD4)-MisL fusion protein detected by western blot analysis. Salmonella SL7207 pZS1205 treated with 0
(lane 1), 11 (lane 2) and 33 (lane 3) μg/ml proteinase K and probed with (A) anti-β-lactamase pAb or (B) anti-OVA-CD4 peptide pAb antibodies,
respectively. (C) Salmonella SL7207 expressing MisL fusion proteins with one (pZS1205, lanes 1 and 6), two (pZS1205-2, lanes 4 and 7) or four
(pZS1205-4, lanes 5 and 8) copies of the OVA-CD4 epitope; untreated (lanes 3 to 5) or treated (lanes 6 to 8) with proteinase K. Bovine albumin
(lane 1) and ovalbumin (lane 2), as negative and positive antibody controls. (D) Salmonella SL7207 pgtE expressing MisL fusion proteins with one
(pZS1205, lane 1), two (pZS1205-2, lane 2) or four (pZS1205-4, lane 3) copies of the OVA-CD4 epitope.
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cells using the NIH ImageJ software suggested that the
OVA-CD4 dimer and tetramer fusion constructs displayed
respectively 2.1 and 3.4 times more epitope as compared
to the monomer construct. Fluorescence intensities with
the PgtE mutant containing the same plasmids showed
similar increases in epitope expression, with 2.4 and 5
times more epitope displayed by the dimer and tetramer
constructs respectively (data not shown). The incremental
levels of fluorescence and western blot bands confirmed
higher expression and surface exposure of the OVA-CD4Figure 5 Confocal microscopy of (A) Salmonella SL7207 labeled with
antibodies, and (B) DAPI-stained Salmonella SL7207. Salmonella SL7207peptide with increased numbers of tandem repeats in the
constructs.
Expression of full-length ovalbumin versus
(OVA-CD4)4-MisL
The relative efficiency of OVA-CD4 epitope expression
harboring pZS1205-4, which encodes the peptide tetramer
fused to MisL, or pUC18-OVA, which encodes the full-
length protein [25], was compared by western blot analysis
with the anti-OVA-CD4 antibody (Figure 6). E. coli was
used as host to compare ovalbumin expression underrabbit anti-OVA-CD4 antibodies and FITC-conjugated anti-rabbit
carried pnirBLTBsp-MisL (I), pZS1205 (II), pZS1205-2 (III) or pZS1205-4 (IV).
Figure 6 Expression of the OVA-CD4 peptide. E. coli JM109
pUC18 (lane 1), with pUC18-OVA uninduced (lane 2) or IPTG-induced
(lane 3) or with pZS1205-4 (lane 4).
Figure 7 In vitro antigen presentation. (A) The CFSE dilution
profile of OTII CD4+ T cells which were co-cultured with APCs that
were either (1) left unpulsed (PBS) or pulsed with Salmonella (2)
SL7207,(3) SL7207pUC18-OVA or (4) SL7207pZS1205-4 [(OVA-CD4)x4].
The cells were gated on CD3+ CD4+ CD45.1+ fraction of the live
lymphocytes. (B) The total numbers of OTII T cells recovered from
the four co-cultures (as labeled above) at the end of the four-day
cultures is shown. The data are representative of three independent
experiments.
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fusion construct was 2.6 or 5.6 times stronger than the
one from the full-length protein with or without IPTG-
induction, respectively.
In vitro antigen presentation
The efficacy of the Salmonella SL7207pZS1205-4 [(OVA-
CD4)4-MisL] constructs in stimulating ovalbumin specific
CD4 T cell responses was tested using in vitro antigen
presentation assays with OTII TCR transgenic system.
The responses obtained with the current construct were
compared to a known full-length ovalbumin expressing
system (pUC18-OVA) that has been used extensively in
the field [25,26], using the same Salmonella strain. The
OTII T cells were labeled with CFSE in these in vitro as-
says and the dilution of CFSE was used to measure T cell
proliferation. When T cells were co-cultured with APCs
pulsed with parental strains of Salmonella that do not ex-
press ovalbumin epitopes, they did not undergo prolifera-
tion as evident from the lack of CFSE dilution (Figure 7A).
APCs pulsed with Salmonella expressing the full length
ovalbumin or (OVA-CD4)4-MisL resulted in activation
of T cells and their proliferation. The OTII T cell expan-
sion was significantly higher in response to (OVA-CD4)4-
MisL as compared to full-length ovalbumin, when each
was expressed by the same Salmonella strain (Figure 7A
and B).
In vivo antigen presentation
To test the efficacy of the various bacterial constructs
in vivo, an adoptive transfer model was used, as de-
scribed in the Methods section. The OTII T cells
expressed the congenic marker CD45.1 and could thus
be tracked in the recipient mice (CD45.2). Seven days
after oral infection with the different bacterial strains,
the mice were euthanized and lymphocytes were isolated
from the spleen and mesenteric lymph nodes and ana-
lyzed by flow cytometry. These studies showed that therewas an increase in the frequency of the OTII T cells dur-
ing infection with the ovalbumin-expressing Salmonella
SL7207 compared to the controls that received PBS or
Salmonella alone (Figure 8A). The frequency of OTII T
cells (CD45.1 CD4+) in the mice that were administered
the strain expressing (OVA-CD4)4 was higher as com-
pared to the mice infected with the strain that expressed
full-length ovalbumin. No deletion of OVA-CD4 repeats
was detected during the time of the in vivo experiment
(data not shown). Based on the analysis of surface
marker expression for activation, such as up regulation
of CD44 and CD25, and down regulation of CD62L,
there was a higher frequency of activated OTII T cells
in the mice infected with the (OVA-CD4)4-expressing
Salmonella (Figure 8B). These differences were also
Figure 8 In vivo antigen presentation. (A) The frequency of OTII CD4+ T cells isolated from the mesenteric lymph nodes of mice that were
administered orally (1) PBS, (2) Salmonella SL7207, (3) SL7207pUC18-OVA or (4) SL7207pZS1205-4 [(OVA-CD4)x4]. The cells were gated on CD4+
CD3+ live lymphocytes and the transferred T cells were identified using the congenic marker CD45.1. (B) The expression of the surface markers
CD62L, CD44 and CD25 on the gated OTII T cells isolated from the four groups described above; PBS (grey area), Salmonella SL7207 (black line),
SL7207pUC18-OVA (blue line) and SL7207pZS1205-4 [(OVA-CD4)x4] (red line). (C) The total numbers of OTII T cells recovered from the mesenteric
lymph nodes of the four groups of mice described above. The data shown are representative of three independent experiments.
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enteric lymph nodes (Figure 8C) and spleens (data not
shown), with significantly higher numbers of OTII T cells
present in the mice infected with the (OVA-CD4)4-ex-
pressing Salmonella compared to the mice infected with
the full-length ovalbumin-expressing Salmonella. To-
gether these data showed that the newly developed con-
struct permits robust expression of the model
ovalbumin epitope both in vitro and in vivo and can be
used as reliable model to track antigen specific T cell
responses.
Discussion
Our studies demonstrated that the MisL autotransporter
protein was capable of displaying the OVA-CD4 epitope
on the surface of Salmonella when the epitope was
grafted onto the amino-terminal side of MisL. Moreover,
MisL fusion proteins engineered to carry the epitope in
tandem copies increased the efficiency of surface display.
Based on our previous work on foreign antigen expression
by Salmonella, we designed a prototype plasmid to
optimize in vivo antigen presentation. For this, a tandem
in vivo inducible promoters was inserted upstream of theOVA-CD4-MisL open reading frame in a low to medium
copy number plasmid and two sets of stabilization systems
were introduced into the construct. When compared to a
traditional Salmonella construct expressing full-length ov-
albumin in the cytoplasm from a multicopy number plas-
mid with a strong constitutive promoter, our prototype
construct expressing four OVA-CD4 epitopes was signifi-
cantly more efficient at presentation for activating CD4 T
cells, both in vitro and in vivo.
A variety of microbes [14,27,28], including wild type
or attenuated entero-invasive Salmonella [16,25,29],
have been genetically modified to express ovalbumin
with its well-characterized CD4 and CD8 T cell epitopes
as a reporter system to study cellular immune responses
in hosts. Many of these studies did not attempt to
optimize the expression level and bacterial delivery
mechanism for the most efficient immune recognition of
the relevant epitopes. For this study, we designed and
tested an improved ovalbumin reporter construct based
on previous studies with Salmonella vaccine vectors that
have established general principles for the improvement
of immune responses. First, surface display of a foreign
epitope was reported to induce a better immune response
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cytoplasm [20]. A recent study suggested that location on
the bacterial surface was even more important for immun-
ity than high abundance or immunodominance since Sal-
monella mainly survive in antigen-presenting cells,
rendering surface antigens more accessible to the cell for
processing and presentation [30]. Second, surface-exposed
foreign epitopes presented as multimers induced better
antibody responses than the same epitopes presented as
monomers on a Salmonella vaccine vector [10]. Because it
is capable of expressing antigens on a Salmonella surface,
the MisL protein has the advantage of tolerating large
fragments of proteins in a fusion construct. This property
was used to incrementally add OVA-CD4 epitopes to
MisL and demonstrated a corresponding stepwise increase
of epitope expression on the surface of Salmonella. The
addition of tandem epitope copies did not affect bacterial
growth. Although surface expression of larger amounts of
foreign epitopes can induce some degradation by the PgtE
protease of Salmonella, as shown previously [24] and here
with four copies of the OVA-CD4 epitope, PgtE did not
significantly affect steady-state expression of the surface
exposed epitope. A third generic rule to improve antigen
delivery for better immune responses is the avoidance of
high copy number plasmids that express large foreign
antigen from constitutive promoters [23,31]. Such vector
constructs are metabolic stressors for the bacteria and are
rapidly eliminated or mutated, resulting in reduced levels
of immune response [22]. In general, metabolic stress can
be minimized by both the use of a low copy number plas-
mid and the expression of the smallest protein fragment
needed for an experimental task, such as a major im-
munogenic epitope fused to a Salmonella protein. Here,
we demonstrated that the multicopy number plasmid
pUC18-OVA that expresses the full-length ovalbumin was
lost in vitro after only a few passages in the absence of
antibiotic selection, suggesting that it is not an optimal
construct. In contrast, the low copy number pZS1204 was
far more stable than pUC18-OVA. Safe remedies to stability
issues for the expression of foreign proteins have been the
use of chromosomal integration or single-copy number
plasmids together with strong constitutive or in vivo indu-
cible promoters [32-34]. As an alternative to stabilize pro-
tein expression, one can borrow plasmid post-segregational
killing genes. We used the latter approach by inserting a
cassette comprising two of these set of genes that we have
previously used with success [10] to obtain pZS1205 and
confirmed significantly improved plasmid stability over 500
generations. In addition, approaches shown to augment the
expression of ovalbumin or other foreign antigens in animal
models were based on the engineering of in vivo-activated
promoters [35-37]. For this study, we took advantage of a
tandem promoter system that we had previously shown to
express antigen efficiently both in vitro and in vivo [10,24].The improved efficiency of antigen presentation with
the engineered Salmonella displaying stably several cop-
ies of the OVA-CD4 epitope on its surface was demon-
strated here by the enhanced CD4+ T cell multiplication
both in vitro and in vivo, using a classical bacterial full-
length ovalbumin construct in the same bacterial back-
ground for comparison. Although we did not evaluate
the individual effect of each construction step on this
immune response, we used a systematic approach based
on an extensive body of literature and our previous stud-
ies to engineer an efficient ovalbumin reporter system.
Among the many autotransporter proteins that are cap-
able of presenting heterologous surface antigens or se-
creted proteins, MisL has already demonstrated its
adaptability as an antigen delivery system in the context
of experimental Salmonella vaccines [7-10,38]. Some of
these studies showed that MisL was tolerant to short
epitope multimers. Here, we confirmed multimer display
with a longer epitope fused to MisL and demonstrated
efficient activation of CD4+ T cells. The identification of
an increasingly larger panoply of autotransporter pro-
teins capable of exporting foreign proteins might help to
partially bypass display or secretion limitations due to
the nature, size and number of epitopes added [4,39].
Although the construct described here was developed to
create an improved ovalbumin reporter system for the
study of CD4+ T cell responses to Salmonella, the con-
cept of epitope presentation in the form of tandemly re-
peated homopolymers might be applicable for other
purposes, including their cytoplasmic delivery by a bac-
terial injection apparatus or invasive mechanism for a
CD8+ T response [10,40,41]. Polymerization of protect-
ive epitopes should also benefit vaccine development.
Methods
Bacterial strains, media and reagents
The bacterial strains used in this study were as follows:
E. coli DH5 alpha (F−φ80lacZΔM15Δ(lacZYA-argF)
U169 recA1 endA1 hsdR17(rk−, mk+) phoA supE44 thi-1
gyrA96 relA1 λ−) [42], JM109 [43], Salmonella enterica
serovar Typhimurium SL7207 (hisG46, DEL407
[aroA544::Tn10 (Tcs)])(derivative of strain SL3261, kind
gift from Dr. Bruce Stocker, Stanford University) [44], S.
Typhimurium χ4550 (gyrA1816ΔasdA1 Δ(zhf-4::Tn10)
Δcrp-1Δcya-1) [45], S. Typhimurium CS4551 (χ4550
phoP::cat) and S. Typhimurium CS4552 (χ4550 pgtE::
aphA) [24]. The SL7207 pgtE mutant was engineered by
generalized transduction, using phage P22. Successful
transfer was confirmed by PCR. All the strains were
grown in Luria-Bertani (LB, Lennox) medium (Difco,
Detroit, MI, USA), with the addition of 50 μg/ml DL-
alpha, ε-diaminopimelic acid (DAP; Sigma, St. Louis,
Mo.) for S. Typhimurium strains χ4550 and CS4551.
Media were supplemented with ampicillin (100 μg/ml),
Table 1 List of plasmids
Plasmids Characteristics Resistance References
pGEM®-T Apr Promega, Madison, WI
pUC18-OVA 1.2 kb ovalbumin gene in pUC18 Apr [25]
pZS1201 pGEM®-T Easy Vector - OVA-CD4 Apr This study
pnirBLTBsp-MisL pnirB for LTsp-MisL, colE1-like ori Apr [7]
pZS1202 pnirBLTBsp-MisL-OVA-CD4 Apr This study
pZS1203 pGEM®-T Easy Vector -spiCp Apr This study
pZS1204 pZS1202 with spiCp Apr This study
pCS238 pACYC184 with ccdAB-flmAB Cmr [10]
pZS1205 pZS1204 with ccdAB-flmAB Apr This study
pZS1205-2 pZS1205 with [OVA-CD4]x2 Apr This study
pZS1205-4 pZS1205 with [OVA-CD4]x4 Apr This study
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Gal (35 μg/ml), and IPTG (0.5 mM), or MgCl2 overnight
[24] when needed or indicated. Restriction and modi-
fication enzymes were from New England Biolabs Inc.
(Beverly, MA, USA). Unless specified otherwise, reagents
were purchased from Sigma.
Plasmid constructs
Table 1 lists all the plasmids used in this study. Plasmids
carrying the genes for MisL-[OVA-CD4]n (n = 1, 2 or 4)
fusion proteins were engineered to be under the control
of two in vivo-inducible promoters in tandem (Figure 1)
[24]. For this, both strands for the ovalbumin
derived CD4 epitope (OVA-CD4: “ISQAVHAAHAEI
NEAGR”) were synthesized as follows: Forward strand:
5′-GCTAGCGGTGGCATTAGCCAGGCCGTGCATGC
GGCCCATGCGGAAATTAACGAAGCCGGCCGCGGT
GGCTCTAGAACTAGTA-3′; Reverse strand: 5′-ACT
AGTTCTAGAGCCACCGCGGCCGGCTTCGTTAAT
TTCCGCATGGGCCGCATGCACGGCCTGGCTAATG
CCACCGCTAGCA-3′. Both strands had an NheI re-
striction site at one end, and XbaI and SpeI restriction
sites at the other end. The 5′ ends were phosphorylated
and the 3′ end had an additional A for TA cloning. The
hybridized strands were ligated into the pGEM®T easy
vector (Promega), resulting in plasmid pZS1201. The
OVA-CD4 epitope containing fragment from NheI and
SpeI, restricted pZS1201 was purified by agarose gel elec-
trophoresis and ligated into the NheI restriction site of
pnirBLTBsp-MisL [7], resulting in plasmid pZS1202. The
spiC promoter from strain χ4550 was amplified by PCR,
using upper primer 5′- ATGCGGATCCAATGCTTCCC
TCCAGTTGCCTGTT-3′ and lower primer 5′-ATGCG-
GAGATCTAAATGGGAGTTTCTATCAAATTC-3′, car-
rying a BamHI or BglII near their 5′ end, [24]. The
amplicon ligated into pGEM®T was designated pZS1203.
The BamHI BglII fragment of pZS1203 carrying the spiC
promoter was ligated into the BglII site of pZS1202, whichis downstream of the nirB promoter sequence [21], result-
ing in pZS1204, as plasmid with tandem promoters. Two
post-segregational killing systems (ccdAB and flmAB)
were amplified by PCR using pCS238 as template and
primers 5′-ATCGTGAATTCCTGCAGACTGGCTGTG
TATAAC-3′ and 5′-ATCGTGAATTCCCTGGCAGTCT
GGTTGTTCAT-3′[10]. The amplicon was restricted with
EcoRI and inserted into the corresponding site of
pZS1204, creating plasmid pZS1205. A second OVA-CD4
epitope was added to the latter plasmid by restricting
pZS1205 with NheI and ScaI or with XbaI and ScaI, and
the two fragments containing the DNA encoding for the
OVA-CD4 epitope were purified by agarose gel electro-
phoresis and ligated to create pZS1205-2. This procedure
was repeated to obtain pZS1205-4, which carries 4 tan-
dem copies of OVA-CD4 DNA as an in-frame fusion to
MisL. All the amplified and cloned PCR products were
checked for sequence accuracy.
Preparation of outer membrane proteins
Outer membrane fractions were prepared from sphero-
plasts, as described previously [46]. Bacteria from 10 ml
overnight cultures (approximately 1010 CFU) were pel-
leted by centrifugation and suspended in 90 μl of
30 mM Tris–HCl (pH 8.0) with 20% sucrose. 10 μl of
lysozyme (1 mg/ml in 0.1 M EDTA) was added and the
bacteria were incubated for 30 min on ice. The obtained
spheroplasts were stabilized with MgCl2 (20 μM final
concentration) and centrifuged (16,000 × g, 2 min). The
periplasmic proteins were removed with the supernatant
and the spheroplasts were resuspended in 100 μl of a
10 mM Tris–HCl (pH8.0), 100 mM NaCl, 10 mM
MgCl2 solution containing 1 μg of DNase per ml, and
lysed by sonication (two times 1 min with a Cup Horn
accessory at amplitude output 10, using a model XL2020
sonicator; Heat System, Farmingdale, N.Y.). Cytoplasmic
membrane proteins were solubilized by incubating the
membranes for 20 min at room temperature with N-
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Ohio) at a final concentration of 0.5% [47]. Residual intact
cells were removed by centrifugation at 1,200 × g for
10 min at 4°C. The non-solubilized outer membranes were
pelleted by high-speed centrifugation in a Beckman JA-18.1
rotor at 17,000 rpm for 3.0 h at 4°C. The outer membrane
pellet was suspended in 200 μl PBS and mixed 1:1 with 2×
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) buffer (sample buffer).
Protease accessibility to surface exposed domains of MisL
fusion proteins
Bacteria grown to log phase (A600 ~ 0.6) were washed in
PBS three times, then divided in four samples. Proteinase
K (recombinant, Roche Diagnostics GmbH, Mannheim,
Germany) was added to final concentrations of 11, 33 or
100 μg/ml, leaving one sample as negative control. The
samples were incubated at 37°C for 30 min, and protease
activity was stopped by adding AEBSF [4-(2-Aminoethyl)
benzenesulfonyl fluoride hydrochloride] to each sample at
final concentration of 0.5 mM. The samples were directly
mixed with 2× sample buffer, heated for 10 min at 100°C,
and 5 μl per lane were analyzed by SDS-PAGE and
western blotting.
SDS-PAGE and western blotting
For SDS-PAGE and western blotting, bacteria grown to
log-phase (A600 ~ 0.6) were pelleted (except for the ex-
periments with isolated outer membranes or using pro-
teinase K, as described above), solubilized in sample
buffer and boiled for 5 min. Proteins were separated by
SDS-PAGE. The gels were analyzed by western blotting,
using affinity purified rabbit anti-OVA-CD4 epitope
(ISQAVHAAHAEINEAGR) polyclonal antibodies (OVA
323–339, Innovagen, Lund, Sweden) diluted 1:1000 in
PBS-0.1% tween 20 (PBS-T) or with rabbit anti-
ampicillinase antibodies (5 prime to 3 prime, Inc. Boulder,
CO), followed by horseradish peroxidase (HRP)-conju-
gated secondary antibodies diluted 1:8000 in PBS-T and
enhanced chemiluminescence (ECL) for detection, as de-
scribed previously [46]. Relative amounts of expressed fu-
sion proteins were evaluated by densitometry, using NIH
ImageJ software version 1.47n (http://rsb.info.nih.gov/ij/).
Indirect immunofluorescence assay (IFA)
For IFA, the bacterial strains were spread on glass slides,
fixed with cold methanol and incubated with rabbit anti-
ovalbumin antibody. The slides were washed three times
with PBS-T, incubated with FITC conjugated goat anti-
rabbit-IgG and washed again with PBS-T. Dried slides
were mounted with 10 μl antifade reagent with DAPI,
overlaid with glass coverslip, and images were acquired
on a Leica TCS SP5 inverted confocal microscope with a
63× (1.2 NA) water immersion lens. Antibody stainingwas visualized with 488 nm excitation from an Argon
laser and DAPI was excited with a 405 nm pulsed diode
laser. Relative fluorescence intensities were calculated
from measurements with the NIH ImageJ software.
Plasmid stability
To determine the persistence of a plasmid in dividing
cells, bacteria were passaged in LB broth without antibi-
otics for 26 days (approximately 530 generations) using
daily 10−3 dilutions of overnight cultures for the first
week and 10−5 dilutions for the remainder. Plasmid sta-
bility was estimated by determining at several passage
points the numbers of antibiotic-resistant live bacteria
containing the plasmid (colony-forming units or CFUs
on ampicillin-containing LB agar plates) divided by the
total number of live bacteria (CFUs on LB agar plates).
This number was multiplied by 100 to obtain a percent-
age of bacteria containing the plasmid [10].
Mice
OTII TCR transgenic mice on a CD45.1 background
were maintained in a specific pathogen-free (SPF) facility
in the Department of Pathobiology at the University of
Pennsylvania in conformance with institutional guide-
lines for animal care. C57BL/6 mice were purchased
from Taconic farms and housed within the SPF facility.
All animal studies were carried out in compliance with
the guidelines of the Institutional Animal Care and Use
Committee of the University of Pennsylvania.
OTII T cell isolation
CD4+ T cells were enriched from lymphocytes isolated
from the spleen and pooled peripheral lymph nodes of
OTII TCR transgenic mice (Ovalbumin specific CD4+
TCR transgenic mice) using CD4+ MACs beads (Miltenyii
Biotech). The cells were labeled with the cytoplasmic dye
CFSE (carboxyfluorescein diacetate succinimidyl ester,
Molecular Probes, Eugene, OR), to track proliferation and
used for the in vitro assays or transferred into mice for
testing in vivo efficacy of the bacterial constructs.
In vitro antigen presentation assay
Antigen-presenting cells were isolated from spleens of
WT mice; CD11C + cells were enriched from RBC lysed
splenocytes using CD11c +MACs beads (Miltenyii Bio-
tech). The purified APCs were resuspended in complete
RPMI (10% FBS) and plated in 24 well plates (1×105
cells/well). The APCs were pulsed with the various bac-
terial constructs at a multiplicity of infection (MOI) of
10 for 2 hours, following which the cells were washed to
remove the extracellular bacteria, treated with gentami-
cin and used for the co-culture studies. The ability of
the pulsed APCs to process and present the ovalbumin
derived from the bacteria on MHC II molecules for T
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with CFSE labeled OTII T cells (5×105 cells/well) for a
period of 4 days, as described previously [14]. At the end
of the culture period, the cells were counted and stained
for flow cytometric analysis.
In vivo antigen presentation assay
2×106 purified OT1I cells (CD45.1) were adoptively
transferred (intravenously) into B6 (CD45.2) recipient
mice and the mice were infected orally 24 hours later.
For infections, log phase cultures of the various bacterial
strains were washed and re-suspended in PBS and ad-
ministered by oral gavage (109 bacteria/mouse). 10 mi-
nutes before infection mice were given 0.1 ml of 5%
NaHCO3 to neutralize the stomach acidity. The mice
were sacrificed on day 7 post infection and the spleens
and mesenteric lymph nodes were harvested for flow cy-
tometric analysis.
Flow-cytometry
Lymphocytes were isolated from spleens and cervical
lymph nodes by mechanical homogenization followed by
lysis of RBCs (for spleens) using lysis buffer (0.846%
NH4Cl). Freshly isolated cells were stained with the anti-
bodies purchased from eBioscience (San Diego, CA) or
BD Biosciences (San Jose, CA). The stained samples
were run on a FACSCanto (BD, San Jose, CA) and re-
sults were analyzed using FlowJo software (TreeStar Inc.,
Ashland, OR).
Statistical significance
Statistical significance of differences between the various
groups was tested using the student’s t test and p < 0.05
was considered significant.
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